CD1A and acute lymphoblastic leukemia: While this approach holds promise, it will only be relevant for a minority of patients with T-ALL with relapsed CD1a+ disease and likely mechanisms of escape will be loss of CD1a expression or selection of a pre-existing CD1a- subclone.